Osiris Therapeutics Receives FDA Fast Track Status For Prochymal As First-Line Treatment For Acute GvHD

Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced that Prochymal has received Fast Track designation from the U.S. Food and Drug Administration (FDA), expediting development of the stem cell therapy as a first-line agent for acute Graft versus Host Disease (GvHD). A Phase III pivotal study for this indication was initiated in November and is now actively enrolling patients. [click link for full article]

More: continued here

Filed under: Immune System / Vaccines on December 15th, 2007